PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Randomized placebo-controlled clinical trials indicate significant and rapid antidepressant effects, starting as early as 1 day after intervention [PMID:34761362].
B. caapi extract improved motor disability in MPTP-treated common marmosets at doses of 56.8 and 113.6 mg/kg [PMID:29368409]. Historical reports from 1929 suggested use of 'banisterine' (harmine) for postencephalitic parkinsonism [PMID:1742748].
Evidence suggests potential for treating substance use disorders, including alcohol use disorder [PMID:26976063, PMID:39523057].
A double-blind, placebo-controlled study on Santo Daime members investigated effects on anxiety and hopelessness, though the provided abstract does not specify the final outcome of the psychometric measures [PMID:17532158].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 38868739 (2023) — Ayahuasca: A review of historical, pharmacological, and therapeutic aspects. · PCN reports : psychiatry and clinical neurosciences
- 2.PMID: 29366418 (2019) — Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. · Current neuropharmacology
- 3.PMID: 34761362 (2022) — Ayahuasca for the Treatment of Depression. · Current topics in behavioral neurosciences
- 4.PMID: 31134518 (2019) — Ayahuasca: Uses, Phytochemical and Biological Activities. · Natural products and bioprospecting
- 5.PMID: 26976063 (2016) — Ayahuasca: Pharmacology, neuroscience and therapeutic potential.